Clínica IMQ Zorrotzaurre, Bilbao, Spain; Universidad de Deusto, Bilbao, Spain.
Unidad Académica de Imagenología Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay.
Radiologia (Engl Ed). 2024 Oct;66 Suppl 2:S132-S141. doi: 10.1016/j.rxeng.2024.05.004. Epub 2024 Nov 8.
Contrast media (CM) were first used soon after the discovery of X-rays in 1895. Ever since, continuous technological development and pharmaceutical research has led to tremendous progress in radiology, more available techniques and contrast media, and expanded knowledge around their indications. A greater prevalence of chronic diseases, population ageing, and the rise in diagnosis and survival times among cancer patients have resulted in a growing demand for diagnostic imaging and an increased consumption of CM. This article presents the main lines of research in CM development which seek to minimise toxicity and maximise efficacy, opening up new diagnostic and therapeutic possibilities through new molecules or nanomedicine. The sector, which is continuously evolving, faces challenges such as shortages and the need for more equitable and sustainable practices.
造影剂(CM)于 1895 年 X 射线发现后不久首次使用。从那时起,不断的技术发展和药物研究导致放射学取得了巨大进展,出现了更多可用的技术和造影剂,并扩展了关于其适应证的知识。慢性疾病的流行、人口老龄化以及癌症患者诊断和存活时间的增加,导致对诊断成像的需求不断增长,造影剂的使用也随之增加。本文介绍了 CM 开发的主要研究方向,这些研究旨在最大限度地降低毒性,提高疗效,通过新的分子或纳米医学为新的诊断和治疗可能性打开大门。这个不断发展的行业面临着短缺和需要更公平、更可持续的实践等挑战。